Results 181 to 190 of about 9,396,775 (321)

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Circulation, 2018
Karen A. Hicks, K. Mahaffey, R. Mehran, Steven E. Nissen, S. Wiviott, B. Dunn, Scott D. Solomon, J. Marler, J. Teerlink, A. Farb, D. Morrow, S. Targum, Cathy Sila, Mary T. Thanh Hai, Michael R. Jaff, Hylton V. Joffe, D. Cutlip, A. Desai, E. Lewis, C. M. Gibson, M. Landray, A. Lincoff, Christopher J. White, Steven S. Brooks, K. Rosenfield, Michael J. Domanski, A. Lansky, J. McMurray, J. Tcheng, S. Steinhubl, P. Burton, L. Mauri, Christopher M. O’Connor, M. Pfeffer, H. Hung, N. Stockbridge, B. Chaitman, Robert J. Temple   +37 more
semanticscholar   +2 more sources

Serum uric acid levels in older adults: Associations with clinical outcomes and implications for reference intervals in those aged 70 years and over

Arthritis Care &Research, Accepted Article.
Objectives Reports have linked both high and low serum uric acid (SUA) levels to adverse health outcomes. This study aimed to establish a reference interval for SUA in older adults and assessed its association with clinically relevant outcomes in relatively healthy, community‐dwelling individuals aged 70 and older.
Amanda J Rickard, Cammie Tran, Hans G Schneider, Flavia M Cicuttini, Anita E Wluka, Ego Seeman, Johannes T Neumann, Md Nazmul Karim, Zhen Zhou, Sultana Monira Hussain, David P Q Clark, Daniel Clayton‐Chubb, Andrew M Tonkin, Lawrence J Beilin, Robyn L Woods, John J McNeil   +15 more
wiley   +1 more source

The times are changing: A primer on novel clinical trial designs and endpoints in critical care research [PDF]

Michael L. Behal, Alexander H. Flannery, Todd A. Miano   +2 more
openalex   +1 more source

Does previous stroke modify the relationship between inflammatory biomarkers and clinical endpoints in CKD patients? [PDF]

, 2022
James Tollitt, Stuart M. Allan, Rajkumar Chinnadurai, Aghogho Odudu, Margaret E. Hoadley, Craig J. Smith, Philip A. Kalra   +6 more
openalex   +1 more source

Exploring patients’ profiles associated with the resolution of acute calcium pyrophosphate arthritis treatedwith colchicine and prednisone: post hoc analysis of a randomized controlled trial

Arthritis Care &Research, Accepted Article.
Objective The objective was to identify factors determining acute arthritis resolution and safety with colchicine and prednisone in acute calcium pyrophosphate (CPP) crystal arthritis. Methods We conducted a post hoc analysis of the COLCHICORT trial, which compared colchicine and prednisone for the treatment of acute CPP crystal arthritis, using a ...
Tristan Pascart, Laurène Norberciak, Pascal Richette, Pierre Robinet, Aurore Pacaud, Gauthier Marchasson, Thibault Rabin, Hélène Luraschi, Pierre Maciejasz, Anne‐France Georgel, Augustin Latourte, Hang‐Korng Ea, Sébastien Ottaviani, Charlotte Jauffret, Vincent Ducoulombier   +14 more
wiley   +1 more source

84 The A-Z of Clinical Trials – Clinical Trial Design Incorporating Efficacy, Translational and Biomarker Endpoints

, 2012
E. Eisenhauer
openalex   +1 more source

Defining endpoints in clinical trials on atrial fibrillation [PDF]

, 2008
A. John Camm, James A. Reiffel
openalex   +1 more source

Effectiveness and safety of baricitinib for juvenile idiopathic arthritis associated uveitis or chronic anterior antinuclear antibody positive uveitis

Arthritis Care &Research, Accepted Article.
Objectives Evaluate the efficacy and safety of baricitinib in paediatric patients with active JIA‐U or chronic anterior ANA‐positive uveitis, who had an inadequate response to MTX or bDMARDs. Methods JUVE‐BRIGHT was an open‐label, active‐controlled, Phase‐3 multicentre trial which utilized a novel design, including 1:1 randomization to an active ...
Athimalaipet V. Ramanan, Catherine M. Guly, Gabriele Simonini, Stuart Keller, Priyanka Sen, Thorsten Holzkaemper, Joana Araújo, Pierre Quartier   +7 more
wiley   +1 more source

ASSESSING THE NET FINANCIAL BENEFITS OF EMPLOYING DIGITAL ENDPOINTS IN CLINICAL TRIALS [PDF]

Joseph A. DiMasi, Abigail Dirks, Zachary Smith, Sarah Valentine, Jennifer C. Goldsack, Thomas Metcalfe, Upinder Grewal, Lada Leyens, Ute Conradi, Daniel R. Karlin, Lesley Maloney, Kenneth Getz, Bert Hartog   +12 more
openalex   +1 more source

From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis

, 2023
Willeke M. C. van Roon‐Mom, Chantal Ferguson, Annemieke Aartsma‐Rus   +2 more
openalex   +2 more sources